ArticleCaspian journal of internal medicine2026
RUNX1-IT1 and AK026392.1 long non-coding RNAs as early predictors of acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation in acute leukemia.
Article in Caspian journal of internal medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Allogeneic hematopoietic stem cell transplantation (allo-HSCT) offers curative potential for hematologic malignancies, yet acute graft-versus-host disease (aGVHD) remains a major complication. Long non-coding RNAs (lncRNAs) regulate immune responses and T-cell differentiation, raising interest in their possible role as biomarkers. This study aimed to evaluate the expression of RUNX1-IT1 and AK026392.1 in peripheral CD4⁺ T cells of allo-HSCT recipients with and without aGVHD. Methods: In a case--control design, 30 acute leukemia patients undergoing allo-HSCT were enrolled. Peripheral blood samples were obtained on day +7 post-transplantation. Patients were monitored for 100 days and classified as aGVHD (n=14) or non-GVHD (n=16) according to NIH criteria. Expression levels of RUNX1-IT1 and AK026392.1 were quantified using qRT-PCR and normalized to ABL. Statistical comparisons and ROC curve analyses were performed to assess diagnostic performance. Results: RUNX1-IT1 expression was significantly elevated in the aGVHD group (~14-fold increase, P=0.012) with an AUC of 0.75, sensitivity 64.3%, and specificity 75%. AK026392.1 showed no statistically significant difference (P=0.114) but demonstrated relatively high specificity (87.5%) with an AUC of 0.67. No significant differences in baseline demographic or clinical characteristics were observed between groups. Conclusion: RUNX1-IT1 upregulation in aGVHD patients supports its potential role in Th1-driven immune responses post-allo-HSCT. While AK026392.1 alone was not significant, its high specificity suggests value in combination with RUNX1-IT1 within multi-marker biomarker panels for aGVHD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.